- Conditions
- Diabetes Mellitus
- Interventions
- Saxagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hyperglycemia, Leukemia
- Interventions
- insulin glargine recombinant, therapeutic insulin
- Biological · Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Surgical Site Infections, Stress Hyperglycemia
- Interventions
- Insulin Lispro Injection, glucose testing
- Drug · Diagnostic Test
- Lead sponsor
- St. Peter's Hospital, Albany, NY
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
- Interventions
- Sitagliptin, glargine, lispro
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes, Inpatient Hyperglycemia
- Interventions
- Insulin glargine, Regular insulin, Insulin glulisine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Hyperglycemia
- Interventions
- Human regular insulin, Insulin lispro, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Physiologic Insulin Therapy, Sliding-Scale Insulin Therapy
- Other
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40,391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Insulin protocol
- Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- AMI
- Interventions
- Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Diabetes Mellitus
- Interventions
- Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes, Hyperglycemia
- Interventions
- sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
- Drug
- Lead sponsor
- Guillermo Umpierrez, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide, Glargine, Rapid-acting insulin analogs
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Heart Failure, Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin 10 MG, Protocolized Diuretic Therapy
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Jackson, Mississippi • Chapel Hill, North Carolina • Oklahoma City, Oklahoma + 1 more
- Conditions
- Diabetes, Hyperglycemia
- Interventions
- sliding scale regular insulin, glargine basal insulin and glulisine prandial insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida